Skip to content
News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Meg Monday
September 14, 2026
Sunvozertinib Improves Time Without Cancer Growth in EGFR Exon 20–Positive Lung Cancer
Meg Monday
August 27, 2026
Daraxonrasib Shows Major Survival Benefit in Metastatic Pancreatic Cancer, Now FDA Approved
Meg Monday
August 4, 2026
FDA Approves Jideytro for Previously Treated ROS1-Positive Lung Cancer
Meg Monday
August 3, 2026
Promising New Option for Claudin 18.2‑Positive Gastric and GEJ Cancer
Meg Monday
July 14, 2026
Shawn’s Story: ctDNA Monitoring After Treatment for Muscle-Invasive Bladder Cancer
Meg Monday
May 5, 2026
Walking Your Way to Recovery: Activity Linked to Less Fatigue in Colorectal Cancer
Meg Monday
May 5, 2026
New Bladder Cancer Immunotherapy Combination Moves Ahead in FDA Review
Meg Monday
April 26, 2026
Study Finds New Treatment Improves Survival in Platinum-Resistant Ovarian Cancer
Meg Monday
February 5, 2026
Mixing Up Your Exercise Routine May Help You Live Longer, Study Finds
Meg Monday
December 14, 2025
Blood Test May Help Predict Recurrence Risk for Early-Stage HR-Positive, HER2-Negative Breast Cancer
Meg Monday
December 8, 2025
FDA Approves New Blood Test to Help Diagnose High-Grade Prostate Cancer
Meg Monday
October 22, 2025
Trodelvy Shows Significant Benefit in Advanced Triple-Negative Breast Cancer
Meg Monday
1
2
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
